|The following article is part of conference coverage from Kidney Week 2017 in New Orleans hosted by the American Society of Nephrology. Renal & Urology News staff will be reporting live on medical studies conducted by nephrologists and other specialists who are tops in their field in acute kidney injury, chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from Kidney Week 2017.|
NEW ORLEANS—Phosphate binder therapy may decrease the risks for infection-related and all-cause death, Japanese researchers reported at Kidney Week 2017.
Shunsuke Yamada, MD, of Kyushu University, and his team analyzed mortality among 2926 hemodialysis (HD) patients from 39 centers in the Q-Cohort Study. Over nearly 4 years of follow-up, 106 patients died from infection. Phosphate binder users had a significant 25% and 37% reduce risk of dying from infection-related causes and all causes, respectively, than patients not taking the drugs.
Results held even after the researchers adjusted for potential confounders. Phosphate binder users had higher body mass index, normalized protein catabolic rate, serum creatinine, and albumin levels than those who did not take the drugs.
“Use of phosphate binders can reduce the risk of infection-related death as well as all-cause death in hemodialysis patients, probably by maintaining good nutritional status,” Dr Yamada told Renal & Urology News.
|Visit Renal & Urology News’ conference section for continuous coverage from Kidney Week 2017.|
1. Yamada S, Tokumoto M, Taniguchi M. Association between use of phosphate-binders and infection-related mortality in hemodialysis patients; the Q-Cohort Study. Presented at Kidney Week 2017 in New Orleans (Oct. 31-Nov. 5). Abstract TH-PO1044.